Last reviewed · How we verify
NCT04970784: URG-GERIA
Impact of a Dedicated Geriatric Sector on the Loss of Functional Autonomy at 1 Month for Patients Admitted to Emergencies and Non-hospitalised
trial testing Activities of Daily Living (ADL) questionnaire (The Katz index ) in Health Services for the Aged in 285 participants. Completed in 21 October 2020.
21 October 2020
Quick facts
| Lead sponsor | Hospices Civils de Lyon |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 285 |
| Start date | 15 June 2020 |
| Primary completion | 21 October 2020 |
| Estimated completion | 21 October 2020 |
| Sites | 1 location across France |
Drugs / interventions tested
- Activities of Daily Living (ADL) questionnaire (The Katz index )
Conditions studied
- Health Services for the Aged — all drugs for Health Services for the Aged →
- Emergency Service, Hospital — all drugs for Emergency Service, Hospital →
- Ambulatory Care — all drugs for Ambulatory Care →
Sponsor
Hospices Civils de Lyon — full company profile →
Who can join
75 and older, any sex, with Health Services for the Aged or Emergency Service, Hospital. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Several studies have shown that going to the emergency room is a risk factor for loss of independence in the elderly. It has been shown that the period following an emergency room visit without hospitalization is a period of vulnerability for the elderly. The functional decline, or loss of functional autonomy, of the elderly is associated with an increase in institutionalization, mortality and costs to society. Studies have highlighted the risk factors for functional decline in the elderly, such as pre-existing functional and cognitive decline, undernutrition, but no model of care has yet prevented the risk of loss of autonomy after a stay in the emergency room. A full and early geriatric assessment could prevent functional decline after the emergency room visit. The primary objective of the study is to assess the impact of a dedicated geriatric sector on the functional decline at 1 month of patients admitted to emergencies without hospitalization by comparing an intervention group (patient having benefited from the geriatric sector) and a group witness ("classic" emergency patient). The secondary objective is to evaluate the impact of this sector on the number of falls at home as well as the readmission rate within 1 month of going to the emergency room.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04970784
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Hospices Civils de Lyon trials
Trials by the same sponsor.
- NCT07569536 — Efficacy of the Alpha 2 Agonist Dexmedetomidine for Sympathetic Deactivation in REfractory Septic Shock · Phase 3 · not yet recruiting
- NCT07529314 — Evaluating Interventional Radiology for Cancer Pain Management · NA · not yet recruiting
- NCT07273929 — Comparative Study of the Effectiveness of Three Access Routes for Implanting an Electronic Intracardiac Device · Phase 3 · not yet recruiting
- NCT07474532 — Attitudes and Beliefs Related to Benzodiazepine Deprescribing · not yet recruiting
- NCT07313007 — Assessment of Gut Microbiota-Derived Amino Acid Metabolite Production in Patients With MASLD · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04970784 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospices Civils de Lyon
- Last refreshed: 21 July 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04970784.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing